WO2009043521A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009043521A3
WO2009043521A3 PCT/EP2008/008104 EP2008008104W WO2009043521A3 WO 2009043521 A3 WO2009043521 A3 WO 2009043521A3 EP 2008008104 W EP2008008104 W EP 2008008104W WO 2009043521 A3 WO2009043521 A3 WO 2009043521A3
Authority
WO
WIPO (PCT)
Prior art keywords
leu
ala
asn
lle
arg
Prior art date
Application number
PCT/EP2008/008104
Other languages
English (en)
Other versions
WO2009043521A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Lab Ag
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Lab Ag, Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher filed Critical Mondobiotech Lab Ag
Publication of WO2009043521A2 publication Critical patent/WO2009043521A2/fr
Publication of WO2009043521A3 publication Critical patent/WO2009043521A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Obesity (AREA)
  • Pediatric Medicine (AREA)
  • Toxicology (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Phe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Thr-Asn-lle-Met-Asn-Leu-Leu-Phe-Asn-lle-Ala-Lys-Ala-Lys-Asn-Leu-Arg-Ala-Gln-Ala-Ala-Ala-Asn-Ala-His-Leu-Met-Ala-Gln-lle-NH2 et Asp-Asn-Pro-Ser-Leu-Ser-lle-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-lle-lle-Phe-Asp-Ser-Val-NH2 en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008104 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique WO2009043521A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017762.1 2007-09-11
EP07017762 2007-09-11
EP07017756.3 2007-09-11
EP07017756 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009043521A2 WO2009043521A2 (fr) 2009-04-09
WO2009043521A3 true WO2009043521A3 (fr) 2009-05-28

Family

ID=40377442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008104 WO2009043521A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009043521A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063046A1 (fr) * 2011-10-24 2013-05-02 Research Development Foundation Procédés d'augmentation de la sécrétion d'insuline par costimulation des récepteurs du facteur de libération de la corticotropine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000063A2 (fr) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Peptides d'urocortine
WO2001072326A1 (fr) * 2000-03-31 2001-10-04 Smithkline Beecham Plc Utilisation d'agonistes des recepteurs de crf pour le traitement ou la prevention de maladies, notamment de maladies neurodegeneratives
WO2007007982A2 (fr) * 2005-07-07 2007-01-18 Postech Foundation Modulateur de captage du glucose et procede de traitement du diabete et des complications du diabete
WO2007090087A2 (fr) * 2006-01-27 2007-08-09 Research Development Foundation Inhibiteurs du recepteur 2 du facteur de liberation de la corticotrophine et ses utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000063A2 (fr) * 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Peptides d'urocortine
WO2001072326A1 (fr) * 2000-03-31 2001-10-04 Smithkline Beecham Plc Utilisation d'agonistes des recepteurs de crf pour le traitement ou la prevention de maladies, notamment de maladies neurodegeneratives
WO2007007982A2 (fr) * 2005-07-07 2007-01-18 Postech Foundation Modulateur de captage du glucose et procede de traitement du diabete et des complications du diabete
WO2007090087A2 (fr) * 2006-01-27 2007-08-09 Research Development Foundation Inhibiteurs du recepteur 2 du facteur de liberation de la corticotrophine et ses utilisations

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ABUIRMEILEH AMJAD ET AL: "The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease", EUROPEAN JOURNAL OF NEUROSCIENCE,, vol. 26, no. 2, 1 July 2007 (2007-07-01), pages 417 - 423, XP002516367 *
BOONPRASERT P ET AL: "Urocortins in heart failure and ischemic heart disease", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 127, no. 3, 21 July 2008 (2008-07-21), pages 307 - 312, XP022794945, ISSN: 0167-5273, [retrieved on 20080103] *
BRAR B K ET AL: "Urocortin-II and Urocortin-III Are Cardioprotective against Ischemia Reperfusion Injury: An Essential Endogenous Cardioprotective Role for Corticotropin Releasing Factor Receptor Type 2 in the Murine Heart", ENDOCRINOLOGY 200401 US,, vol. 145, no. 1, 1 January 2004 (2004-01-01), pages 24 - 35, XP002515893 *
DAVIDSON S M ET AL: "The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family", BIOCHEMICAL PHARMACOLOGY 20090115 US, vol. 77, no. 2, 15 January 2009 (2009-01-15), pages 141 - 150, XP002517672, ISSN: 0006-2952 *
GONZALEZ-REY ELENA ET AL: "Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells", ARTHRITIS & RHEUMATISM,, vol. 56, no. 2, 1 February 2007 (2007-02-01), pages 531 - 543, XP002516366 *
KOZAK ET AL.: "The corticotropin-releasing factor type 2 receptor selective ligand Urocortin 3 suppresses angiogenesis in vitro and in vivo", ENDOCRINE ABSTRACTS, vol. 13, no. OC23, 5 March 2007 (2007-03-05), Birmingham, XP002517671, Retrieved from the Internet <URL:http://www.endocrine-abstracts.org/ea/0013/ea0013oc23.htm> [retrieved on 20090302] *
LIU CHUN-NA ET AL: "In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY,, vol. 83, no. 6, 1 June 2005 (2005-06-01), pages 459 - 465, XP009112511, ISSN: 0008-4212 *
RADEMAKER MIRIAM T ET AL: "Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure", EUROPEAN HEART JOURNAL SEP 2006,, vol. 27, no. 17, 1 September 2006 (2006-09-01), pages 2088 - 2098, XP002515894 *
SPINA MARIAROSA ET AL: "Appetite-suppressing effects of urocortin, a CRF-related neuropeptide", SCIENCE (WASHINGTON D C),, vol. 273, no. 5281, 1 January 1996 (1996-01-01), pages 1561 - 1564, XP002516368 *
WANG JUEJIN ET AL: "Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2", CANCER INVESTIGATION, MARCEL DEKKER INC, US, vol. 24, no. 6, 1 May 2008 (2008-05-01), pages 359 - 368, XP009112501, ISSN: 0735-7907 *
YANG C ET AL: "Effects of intravenous urocortin on angiotensin-converting enzyme in rats", VASCULAR PHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 4, 1 April 2006 (2006-04-01), pages 238 - 246, XP024969980, ISSN: 1537-1891, [retrieved on 20060401] *

Also Published As

Publication number Publication date
WO2009043521A2 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043518A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033797A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
LTC2435432I2 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
WO2009126688A3 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2009002423A3 (fr) Dérivés de guanine polycycliques et leurs procédés d&#39;utilisation
WO2012061390A3 (fr) Compositions et procédés thérapeutiques
WO2009033819A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
WO2007135026A3 (fr) Ptéridines substituées
WO2012024282A3 (fr) Composés de 1,5-diphényl-penta-1,4-dién-3-one
IL200091A0 (en) Use of chitosans for the treatment of nail inflammatory diseases
WO2006089664A3 (fr) Imidazoles substitues par heterocyclylamide
WO2010094734A3 (fr) Procédés d&#39;identification de composés utiles pour le diagnostic et le traitement de maladies liées à une inflammation
WO2009043525A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033818A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033813A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033814A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033820A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009043521A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2008009426A9 (fr) Dérivés de 5-cyano-prostacycline utilisés comme agents dans le traitement de maladies auto-immunes
WO2009033809A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009074498A8 (fr) Nouvelle utilisation médicale de l&#39;orotate de propionate de 3-(2,2,2-triméthylhydrazine)
WO2010149357A3 (fr) Méthodes de traitement du cancer utilisant la corticolibérine (crf)
WO2009043523A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802579

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802579

Country of ref document: EP

Kind code of ref document: A2